

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Centre for Clinical Practice – Surveillance Programme

### *Recommendation for Guidance Executive*

#### **Clinical guideline**

CG145: Spasticity in children and young people with non-progressive brain disorders

#### **Publication date**

July 2012

#### **Surveillance report for GE**

December 2014 (2 year surveillance review)

#### **Surveillance recommendation**

GE is asked to consider the proposal to not update the guideline CG145: Spasticity in children and young people with non-progressive brain disorders, where no impacts were identified by the Evidence Update. GE is asked to note that this 'no to update' proposal will not be consulted on.

#### **Key findings**

			Potential impact on guidance	
			Yes	No
Evidence identified from Evidence Update				✓
Anti-discrimination and equalities considerations				✓
No update	CGUT update	Standard update	Transfer to static list	Change review cycle
✓				

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Centre for Clinical Practice – Surveillance Programme

### Surveillance review of CG145: Spasticity in children and young people with non-progressive brain disorders

#### *Recommendation for Guidance Executive*

#### ***Background information***

Guideline issue date: July 2012

NCC: Women's and Children's Health

#### ***Main findings of the current two year surveillance review***

1. The [Evidence Update](#) on CG145: Spasticity in children and young people with non-progressive brain disorders was used as the primary source of evidence for this surveillance decision (search dates: 8<sup>th</sup> August 2011 to 30<sup>th</sup> June 2014). A summary of the evidence is provided in the Evidence Update.
2. The Evidence Update indicates that there is currently insufficient new evidence to invalidate the existing guideline recommendations therefore the Surveillance Programme recommends no update at this time.

#### ***Ongoing research***

3. Not considered at the 2-year review point.

#### ***Anti-discrimination and equalities considerations***

4. None identified through the Evidence Update.

***Implications for other NICE programmes***

5. None identified through the Evidence Update.

***Surveillance recommendation***

6. GE is asked to consider the proposal to not update the guideline at this time. GE is asked to note that as a 2-year surveillance decision this 'no to update' proposal will not be consulted on.

Mark Baker – Centre Director  
Sarah Willett – Associate Director  
Diana O'Rourke – Technical Analyst

Centre for Clinical Practice  
December 2014